Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2.

Participants are put into 13 groups based on the type of advanced cancer and the type of HER2 alterations they have. All participants take one dose of zongertinib each day. Participants can continue the treatment as long as they benefit from it and can tolerate it.

Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.

Official Title

Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours

Keywords

Solid Tumours, Zongertinib

Eligibility

Locations

  • University of California Los Angeles not yet accepting patients
    Los Angeles California 90095 United States
  • Scripps Cancer Center Torrey Pines not yet accepting patients
    La Jolla California 92037 United States
  • The University of Texas MD Anderson Cancer Center accepting new patients
    Houston Texas 77030 United States
  • Alaska Oncology and Hematology, LLC accepting new patients
    Anchorage Alaska 99508 United States

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Boehringer Ingelheim
Links
Related Info
ID
NCT06581432
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 200 study participants
Last Updated